Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
Molecular Oncology, EarlyView.In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley +1 more source
Introduction: Inflammatory bowel disease: a complex systemic disease engaging multiple players outside the immune system [PDF]
, 2008 Susanne Pettersson
openalex +1 more source
Myeloid-derived suppressor cells as regulators of the immune system
Nature reviews. Immunology, 2009 D. Gabrilovich, S. Nagaraj
semanticscholar +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
A cytokine-enhanced viral infection model with CTL immune response, distributed delay and saturation incidence [PDF]
arXivIn this paper, we propose a delayed cytokine-enhanced viral infection model incorporating saturation incidence and immune response. We compute the basic reproduction numbers and introduce a convex cone to discuss the impact of non-negative initial data on solutions.
arxiv
Roles of HLA-II molecules on the immune system in periodontal disease
, 2000 openalex +2 more sources
Morbus Crohn--a disease of failing macroautophagy in the immune system? [PDF]
, 2009 Sonja Meixlsperger, Christian Münz
openalex +1 more source
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen +12 more
wiley +1 more source
Immune System Dysfunction and Autoimmune Disease in Mice Lacking Emk (Par-1) Protein Kinase
, 2001 Jonathan Hurov +8 more
openalex +1 more source
Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?
Molecular Oncology, EarlyView.Chen‐xi Li, Zhong‐cheng Gong
wiley +1 more source